In light of the strong desire to shorten timelines and lower cost for biologics such as monoclonals specially biosimilars, and address surging demand for complex proteins such as bispecific antibodies, the biopharmaceutical industry is re-evaluating traditional manufacturing methods that have been a staple of drug development for decades. Successfully developing new therapy modalities requires sustainable strategies and technologies that maximize production. To address limitations with existing bioprocesses, manufacturers are increasingly turning to biopharma partners like Sartorius for progressive process intensification solutions and strategies—that improve bioprocess efficiency and productivity—to deliver the next generation of biologic drugs.
In this webinar, our expert speakers will share their journey of implementing intensified technologies and its potential to improve the efficiency and cost-effectiveness of biologics manufacturing. You’ll hear about the latest market and technology trends and learn about innovative continuous manufacturing solutions that are already helping biomanufacturers improve productivity. You’ll also learn about important considerations for adopting a process intensification strategy and how this can enhance process safety and enhance environmental impact.
.
